Vol. 4 No. 1 (2016): March 2016

Published: 2016-03-31

Editorial

Prostate cancer resistance to second generation hormonal agents

Mélanie Claps, Chiara Foroni, Alfredo Berruti

3-5
- PDF

Review

Use of first-line trabectedin in advanced leiomyosarcoma: a review of clinical data and future perspectives

Nadia Hindi, Florence Duffaud, Giacomo Giulio Baldi, Patricia Pautier

6-10
- PDF

Pro & Cons editorial

Role of surgery in the multidisciplinary treatment of malignant pleural mesothelioma

Federico Rea, Paolo Andrea Zucali, Lorenzo D’Ambrosio

11-16
- PDF

Breaking from the Lab

Next generation sequencing (NGS) in oncology: lights and shadows

Margherita Nannini, Maria A. Pantaleo

17-19
- PDF

Clinical original article

Aprepitant plus palonosetron as salvage therapy for CINV induced by moderately emetogenic chemotherapy in cancer patients

Bruno Vincenzi, Anna Maria Frezza, Marianna Silletta, Emanuela Dell’Aquila, Giovanna Catania, Daniele Santini, Giuseppe Tonini

20-25
- PDF
Systemic management of malignant ovarian germ cell tumors in older women: two case reports and a review of the literature

Michael Luis, Stergios Boussios, Lucy Dumas, Susana Banerjee

26-35
- PDF

Meet the expert

Case 1 – Long-term response to bevacizumab and paclitaxel as second-line therapy in metastatic vaginal carcinoma

Sebastian Schroecksnadel, Jasmina Suljkanovic, Christian Marth, Antonio González-Martín, Domenica Lorusso

36-40
- PDF
Case 2 – Trabectedin as a maintenance therapy in a patient with recurrent ovarian cancer and BRCA1 germline mutation

Filippo Greco, Paolo Piacentini, Andrea Remo, Andrea Bonetti, Gabriella Ferrandina

41-44
- PDF

Methodological corner

Bevacizumab as first-line treatment of ovarian cancer: strengths and weaknesses of subgroup analyses

Sandro Pignata, Sabrina Chiara Cecere, Massimo Di Maio

45-47
- PDF

Letter to the Editor

Letter to the Editor

Lorenzo D’Ambrosio, Ymera Pignochino, Giovanni Grignani

48-50
- PDF